Reversibility of vigabatrin-induced visual-field defect

Lancet

Volumn 354, Issue 9177, 1999, Pages 486-

  Versino, M ^a   Veggiotti, P ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; VIGABATRIN; 4 AMINOBUTYRIC ACID; DRUG DERIVATIVE;

ARTICLE; CASE REPORT; CHILD; DRUG WITHDRAWAL; EPILEPSY; FEMALE; HUMAN; PRIORITY JOURNAL; SCHOOL CHILD; VISUAL FIELD DEFECT; DRUG EFFECT; FOCAL EPILEPSY; FOLLOW UP; LETTER; PERIMETRY; VISUAL FIELD;

ANTICONVULSANTS; CHILD; EPILEPSIES, PARTIAL; FEMALE; FOLLOW-UP STUDIES; GAMMA-AMINOBUTYRIC ACID; HUMANS; PERIMETRY; VIGABATRIN; VISUAL FIELDS;

EID: 0033533022     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)02095-4     Document Type: Article

References (5)

1. T Eke JF Talbot MC Lawden Severe persistent visual field constriction associated with vigabatrin BMJ 314 1997 180 181
2. GL Krauss MA Johnson NR Miller Vigabatrin-associated retinal cone system dysfunction Neurology 50 1998 614 618
3. K Ruether T Pung U Kellner B Schmitz C Hartman M Seelinger Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin Arch Opthalmol 116 1998 817 819
4. A Roubertie H Bellet B Echenne Vigabatrin-associated retinal cone system, dysfunction Neurology 51 1998 1778 1779
5. R Kalviainen I Nouvasianen E Nikoskelainen Visual defects associated with initial vigabatrin monotherapy as compared with initial carbamazepine monotherapy Epilepsia 39 suppl 2 1998 5